PPO MultiPlan Covering GenomeDx's Prostate Cancer Test | GenomeWeb

NEW YORK (GenomeWeb) – Prostate cancer diagnostics firm GenomeDx today announced it has signed a contract with MultiPlan for diagnostic laboratory testing.

As result of the deal, members of the preferred provider organization will have access to GenomeDx's Decipher Prostate Cancer Classifier, which measures a patient's biological risk of developing metastatic prostate cancer. MultiPlan has more than 500,000 providers in its network.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.